Y. Shi

发表

Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo

M. Wang, L. Kwak, J. Yang, 2008, Leukemia.

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)

T. Mok, Y. Ichinose, M. Maemondo, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Etoposide 1.0 g/m2 or 1.5 g/m2 combined with granulocyte colony-stimulating factor for mobilization of peripheral blood stem cells in patients with malignancy: efficacy and toxicity.

C. Zhang, X. He, P. Liu, 2009, Cytotherapy.

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.

K. O'Byrne, T. Mok, E. Tan, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

A practical procedure for the cryopreservation of marrow cells intended for autotransplantation.

Y. Shi, F. Feng, K. Luo, 1995, Leukemia & lymphoma.

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study

B. Han, K. Li, P. Yu, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

K. O'Byrne, T. Mok, E. Tan, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).

T. Mok, Y. Ichinose, M. Maemondo, 2017 .

Clostridium difficile infection in hospitalized cancer patients in Beijing, China is facilitated by receipt of cancer chemotherapy.

Z. Jiang, H. Dupont, Y. Shi, 2013, Anaerobe.

[Clinical research and drug review of epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer].

M. Zhou, Y. Shi, L. Xia, 2019, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[The development of biosimilars in oncology].

Y. Shi, S. Jiang, 2017, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[The development and main achievements of clinical trials for anti-cancer investigational new drug in the past 60 years in China (1960-2020)].

Y. Shi, Y. Sun, 2021, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[The differential diagnosis of pulmonary infiltrates in cancer patients during the outbreak of the 2019 novel coronavirus disease].

J. Huang, X. He, F. Ma, 2020, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[Prognostic significance of inflammatory indicators for advanced-stage diffuse large B-cell lymphoma].

C. Zhang, X. He, P. Liu, 2018, Zhonghua yi xue za zhi.